



**World Health  
Organization**

**Draft agenda**  
**Meeting of the Immunization Strategic Advisory Group of Experts**  
**9-11 November 2005**  
**Centre International de Conférences de Genève,**  
**17 rue de Varembe, Geneva**

**Wednesday 9 November**

<b>Time</b>	<b>Session</b>	<b>Target outcomes and questions for SAGE</b>	
09:00	<b>Welcome - introduction</b>	Stage set	15 mn
09:15	<b>Report from Director of Department of Immunization, Vaccines and Biologicals</b> Presentation JM. Okwo-Bele 15 mn  Discussion 15 mn	Changes to SAGE and to the Department highlighted  Report to SAGE on achievement of previous recommendations	30 mn
09:45	<b>Regional priorities, major policy and implementation issues</b> AFRO 15 mn      D. Nshimirimana AMRO 15 mn      J. Andrus EMRO 15 mn      S. Youssouf EURO 15 mn      N. Emiroglu SEARO 15 mn      M. Linder WPRO 15 mn      Y. Baoping  Discussion 45 mn	For information and to help SAGE define priorities for global immunization	2.25hrs

10:30	Coffee break		30 mn
11:00	<b>Regional priorities, major policy and implementation issues (ctd)</b>		
12:30	Lunch		1.5 hr
14:00	<p><b>Global Immunization Vision and Strategy (GIVS): major strategic approaches, costing and financing of the global immunization</b></p> <p>Outline of the major strategic approaches and challenges for the implementation of GIVS by UNICEF 15 mn P. Salama</p> <p>Outline of the major strategic approaches and challenges for the implementation of GIVS by WHO: Proposed WHO HQ strategic plan 15 mn R. Eggers</p> <p>Discussion 50 mn</p>	<p>Does the WHO Strategic Plan 2006 - 2009 reflects the expected WHO contribution in implementing the GIVS?</p> <p>In addition to the WHO and UNICEF strategic directions, what areas within GIVS should - in the next two years - be emphasized?</p>	3 hrs
15:20	<b>Coffee break</b>	Break	30 mn
15:50	<p><b>GIVS continued</b></p> <p>GAVI: Current and future funding mechanisms (includes IFFim info) 20 mn J. Lob-Levyt</p> <p>Estimated costing of the GIVS (<i>includes elements of future funding</i>) 20 mn L. Wolfson</p> <p>Discussion 50 mn</p>	<p>What are the needs in terms of further costing studies?</p> <p>Is this WHO's role to engage in dynamic cost models?</p>	
17:20	<p><b>Reports from other advisory committees in immunization: open question time</b></p> <ul style="list-style-type: none"> <li>-Global Advisory Committee on Vaccine Safety</li> <li>-Immunization safety priority project steering committee</li> <li>-IVR Advisory Committee</li> <li>-Advisory Committee on Polio Eradication and Supplement to the IPV position paper</li> <li>-Expert Committee on Biological Standardization</li> </ul>	<p>Inform SAGE of key conclusions and recommendations from other advisory committees and allow SAGE to request clarifications</p> <p>Allow SAGE to comment on directions from the Supplement to the IPV position paper</p>	40 mn

<b>18:00</b>	<b>End of day</b>		
--------------	-------------------	--	--

## Thursday 10 November

08:30	<p><b>Influenza with particular focus on the role of vaccination in pandemic preparedness</b></p> <p>Current status of availability of pandemic vaccines and prospects for supply 15 mn K. Stöhr</p> <p>Strategies to shorten the time between emergence of a pandemic virus and the start of commercial production 10 mn J. Wood</p> <p>Strategies to accelerate registration of pandemic vaccines 30 mn</p> <p>EU approaches: P. Celis USA approaches: TBC Developing country approaches: S. Nishioka</p> <p>Increasing the supply of influenza vaccines; an industry perspective 10 mn L. Hessel</p> <p>Increasing the supply of influenza vaccines in developing countries; current issues and activities - 10 mn S. Chunsuttiwat</p> <p>Proposed WHO programme of work on influenza vaccines 10 mn D. Wood</p> <p>Discussion 1 hr</p>	<p>Analysis of the role of seasonal and pandemic vaccination in influenza pandemic response and identification of needed further information would to decide on this role</p> <p>Challenges in vaccine development and registration in preparation of an influenza pandemic addressed</p> <p>Evaluate options to increase influenza vaccine availability during a potential pandemic</p> <p>Advice that WHO should give to non-industrialized countries on how to increase availability to influenza pandemic vaccines defined</p> <p>WHO activities in the area of vaccines in preparation of a potential pandemic</p>	2.5 hrs
-------	--	---	---------

<b>10:00</b>	Coffee break	Break	30 mn
10:30	<b>Influenza continued</b>		
11:30	<p><b>Strategic challenges for <i>Haemophilus influenzae</i> type b (Hib)</b></p> <p>Issues related to Hib vaccines including report of informal consultations on disease burden in AFRO and ASIA 15 mn P. Zuber</p> <p>Challenges to Hib surveillance in Africa 15 mn B. Mhlanga</p> <p>The Hib initiative 15 mn R. Hajjeh</p> <p>Vaccine supply study 15 mn J. Milstien</p> <p>Discussion 1 h</p>	<p>Given the new opportunity presented by the Hib Initiative, what should be the timeline and process to come-up with revised recommendations for vaccine use?</p> <p>For countries that consider introducing Hib vaccine, should there be a recommendation on establishing sentinel surveillance?</p> <p>Should a global recommendation on vaccine use take into consideration the global vaccine supply landscape?</p>	2 hrs
<b>12:30</b>	Lunch		1.5 hr
14:00	<b>Hib continued</b>		
<b>15:00</b>	Coffee break		30 mn
15:30	<p><b>Challenges for rotavirus vaccines introduction</b> <u>Update of Rotavirus Vaccine Research and Development</u> (30 mn - 10 mn each)</p> <ul style="list-style-type: none"> <li>Status of the development, licensing and plans for introduction of Rotarix™ TBC</li> <li>Status of the development, licensing and plans for introduction of RotaTeq™ TBC</li> </ul>	<p>What do we still need to consider for rotavirus vaccine introduction?</p> <p>Is the existing evidence sufficient to warrant a global recommendation for use?</p> <p>Does the available evidence and burden of disease warrant a regional</p>	2.25 hrs

	<ul style="list-style-type: none"> <li>• Status of the alternative rotavirus vaccine candidates R Glass</li> </ul> <p>Discussion 15 mn</p> <p><u>Rotavirus Vaccine Introduction (30 mn - 10 mn each)</u></p> <ul style="list-style-type: none"> <li>• Building the evidence base for rotavirus vaccine Introduction in countries K Neuzil</li> <li>• Plans for rotavirus vaccine introduction in countries in the PAHO region J Andrus</li> <li>• Remaining challenges for rotavirus vaccine introduction and a global recommendation D Steele</li> </ul> <p>Discussion 60 mn</p>	<p>recommendation?</p> <p>What is still required for a global recommendation?</p>	
<b>17:45</b>	<b>End of day</b>		

## Friday 11 November

08:30	<p><b>Human Papilloma virus vaccine (planning for introduction)</b></p> <p>Update of HPV vaccine situation: disease burden and progress on vaccine development 15 mn S. Franceschi</p> <p>Planning for introduction</p> <p>The Gates grants to WHO, IARC, PATH, and the WHO information centre and the setting up a network of laboratories 10 mn S. Pagliusi</p> <p>Feedback from the HPV Expert Advisory Group consultation &amp; follow-up on recommendations 15 mn F. Cutts</p> <p>Discussion 20 mn</p>	Information on disease burden and vaccine development and review of the main challenges for vaccine introduction	1 hr
09:30	<p><b>Conjugate pneumococcal vaccines: review of evidence and requirements for a global recommendation</b></p> <p>Current situation with pneumococcal conjugate vaccines including outcomes/status of clinical trials in Africa and Asia - T. Cherian 20 mn</p> <p>GAVI's PneumoADIP - O. Levine 15 mn</p> <p>Discussion 10mn</p>	<p>Directions to WHO and the PneumoADIP on the information required for a SAGE recommendation on vaccine use</p> <p>Is the existing evidence on disease burden, vaccine efficacy, and vaccine safety sufficient for a global recommendation to use the vaccine in all developing countries?</p> <p>What additional data (including</p>	2 hrs

	<p>Supplier updates (30 mn)</p> <p>Pneumo vaccine overview from BCG study J Milstien 10 mn</p> <p>GSK – 10 mn – updates on product development and comment on willingness to serve developing country market and conditions</p> <p>Wyeth – 10 mn -- updates on product development and comment on willingness to serve developing country market and conditions</p> <p>Discussion 40 mn</p>	information related to vaccine supply and/or financing) are required for a global or regional recommendation?	
<b>10:30</b>	Coffee break		30 mn
11:00	<b>Pneumo continued</b>		
<b>12:00</b>	Lunch		1 hr
13:30	<p><b>Optimizing immunization schedules</b></p> <p>The EPI immunization schedule - is it still optimal 30 mn N. Halsey</p> <p>Expanding vaccination beyond the traditional target group: what, when, and how? 30 mn F. Cutts</p> <p>Discussion 1 hr</p>	<p>Identify major issues to be addressed in relation with optimization of immunization schedules.</p> <p>Determine priority issues to be reviewed at the next SAGE meeting.</p> <p>Outline approach to be used in addressing priority issues.</p>	2 hrs
15:30	<b>Closing</b>		30 mn
16:00	<b>End of meeting</b>		